Adagene Inc at HC Wainwright Investment Conference - New York Transcript

Sep 13, 2023 / 04:00PM GMT
Arthur He - H.C. Wainwright & Co., LLC - Analyst

All right, let's hit it. Good afternoon, everyone. My name is Arthur He, senior biotech analyst at H.C. Wainwright. Thanks for joining us to have a conversation with Dr. Peter Luo, the Chairman, CEO, and the Co-Founder of Adagene.

Adagene is a clinical-stage biopharmaceutical company focused on develop a novel antibody-based cancer therapy based on its proprietary platform, which including NEObody, POWERbody, and the SAFEbody. So the company currently has four clinical-stage assets and a number of preclinical programs. To discuss this program and the development strategy, I'd like to invite Peter to this conversation. Peter, thanks for coming down to talk to our audience.

Peter Luo - Adagene Inc. - Chairman, CEO, Co-Founder & President of R&D

Thanks, Arthur.

Arthur He - H.C. Wainwright & Co., LLC - Analyst

So just to help set the stage for our audience, could you give us an overview about the Adagene pipeline right now?

Peter

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot